Chandrabali Ghose, Ph.D.
Founder and CEO
Chandra received her undergraduate education in Biology and Theology from Saint Louis University, splitting her time between the Madrid, Spain and Saint Louis, Missouri campuses. Subsequently, she moved to New York University where she earned her PhD in Basic Biomedical Sciences from the Department of Microbiology. Chandra completed her postdoctoral training at Harvard Medical School, before joining the laboratory of Dr. David D. Ho at the Aaron Diamond AIDS Research Center, Rockefeller University. She ran the Clostridium difficile vaccine and therapeutics program as a Research Scientist till 2015. Before she started Bioharmony Therapeutics in July of 2016, Chandra was the CSO of Symbiotic Health, a startup focused on the development of therapies for Clostridium difficile infections.
Chris N. Garabedian.
Chairman of the Board of Directors
Chris Garabedian founded Xontogeny in 2016 to support multiple promising technologies from early development through clinical proof of concept. Most recently, Chris served as the President and CEO of Sarepta Therapeutics from 2011 to 2015, Chris has a broad base of experience and a track record of success across his 25 years in the pharma and biotech industries, including at two of the most successful biopharma companies over the last 20 years, Gilead and Celgene. Prior to Celgene, Chris served in a number of global leadership roles at Gilead from 1997 to 2005, including as VP of Corporate Development, VP of Medical Affairs and VP of Marketing. Chris is currently on the Board of Directors of MassBio, on the Board of Advisors for the Keck Graduate Institute and serves as a Senior Advisor for the Boston Consulting Group to their healthcare practice group.
Vincent A. Fischetti, Ph.D.
Scientific Advisory Board
Dr. Fischetti is the Head of the Laboratory of Bacterial Pathogenesis and Immunology at the Rockefeller University. Dr. Fischetti has been on the faculty of Rockefeller University since 1973. Dr. Fischetti is the leading expert and discoverer of lysins. Technology from his laboratory is currently being developed for the treatment of MRSA, Clostridium difficile and many others bacterial pathogens. He has authored more than 200 publications and holds more than 40 patents in therapeutics, devices and diagnostics space.
SUPPORTED BY :